Eastern Cooperative Oncology Group

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 5(6) 649-655. 

Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004 10 1670-1677. 

Single-agent activity of paclitaxel was initially evaluated by the Eastern Cooperative Oncology Group (ECOG) in a select cohort of 34 patients with unresectable, recurrent, or metastatic disease (34). The overall response rate was 40% (4 CR, 8 PR). Myelosuppression was the primary toxicity. The median survival was 9.2 mo with a 1-yr survival of 33%. 

The Eastern Cooperative Oncology Group has studied the combination of high-dose paclitaxel and cisplatin with G-CSF support in comparison to low-dose paclitaxel and cisplatin in a recent phase III trial (77). Patients with locally advanced, recurrent, or metastatic disease were randomly placed on arm A of paclitaxel (200 mg/m2 over a 24-h infusion), cisplatin (75 mg/m2), and G-CSF (starting d 3 until the ANC was >10,000/pL) or armB ofpaclitaxel (135 mg/m2 over a 24-h infusion) and cisplatin (75 mg/m2). The tre atment was repeated every 21 d until progression of disease or a total of 12 cycles. 

Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998 82 2270-2274. 

Clamon G. Herndon J. Cooper R, et al. Radiosensitization with carboplatin forpatients with unresectable stage III non-small-cell lung cancer A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J Clin Oncol 1999 17 4—11. 

Smith TJ, Ryan LM, Douglass HO Jr, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998 42(2) 269-276. 

Hoffman JP, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998 16(1) 317—323. 

Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994 12 483-488. 

Roth BJ, Dreicer R, Einhom LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium aphase II trial of the Eastern Cooperative Oncology Group (El 892). J Clin Oncol 1994 11 2264-2270. 

FaUcson G, Gelman R, FaUcson Cl, Click J, Harris J. Factors predicting for response, time to treatment failure and survival in women with metastatic breast cancer treated with DAVTH a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991 9 2153-61. 

Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin s disease Eastern Cooperative Oncology Group pilot smdy E1492. J Clin Oncol 2000 18 972-80. 

Wadler S, Levy DE, Lincoln ST, Soori GS, Schink JG, Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma Eastern Cooperative Oncology Group smdy E3E93. J Clin Oncol 2003 21 2110-4. 

Falkson, C.I., J. Ibrahim, J.M. Kirkwood, A.S. Coates, M.B. Atkins, and R.H. Blnm, Phase HI trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma an Eastern Cooperative Oncology Group study. J Clin Oncol, 1998.16(5) 1743-51. 

Langer CJ, Stephenson P, Thor A et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer is there a role Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 2004 22 1180-1187. 

M. E. M., Wolf, B., Sabatini, L., Jett, J., Kohman, L., and Johnson, D. H. 2001. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell cancer on E4592 A laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. 7. Clin. Oncol. 79 448-457. 

Dreicer R, Proper KJ, Roth BJ, Einhorn LH, Loehrer PJ. Vinblastine, ifosfamide, and gahium nitrate—an active new regimen in patients with advanced carcinoma of the uro-thehum. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Cancer 1997 79(1) 110-14. 

Trump DE, Elson P, Brodovsky H,VoglSE. Carboplatin in advanced, refractory germ cell neoplasms a phase II Eastern Cooperative Oncology Group Study. Cancer Treat Rep. 1987 Oct 71 [10] 989-90... 

Source. Eastern Cooperative Oncology Group, "ECOG Performance Status," URL http //ecog.dfci.harvard.edu). 

The presence of other disease states may also affect response to treatment by limiting treatment options. The overall functional status of a patient may be assessed using performance status scales, such as the Karnofsky and Eastern Cooperative Oncology Group scales (Table 124-9). These scales can be used to predict patient tolerance of chemotherapy, as well as to assess the effects of chemotherapy on the patient s level of activity and quality of hfe. In many cancers, performance status at diagnosis is the most important prognostic indicator. 

Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000 18 623-631. 

---